Key Highlights
- Revenue was USD 52.03 million against an estimate of USD 52.51 million.
- EPS was USD 0.16 against an estimate of USD 0.13.
- Nine-month revenues were a record USD 152.2 million, per management.
- 2026 Revenue guidance was raised to USD 205 million to USD 208 million.
Kamada (NASDAQ:KMDA) reported third quarter 2026 revenue of USD 52.03 million, against an estimate of USD 52.51 million. EPS was USD 0.16, compared with an estimate of USD 0.13. Management said it continued the strong operational and financial performance of the year, with double-digit growth in revenues and adjusted EBITDA for both the quarter and the nine-month period.
Chief executive officer Amir London opened the call, and the chief financial officer reviewed the financial results and guidance.
Nine-Month Results
Management said total revenues for the nine-month period were a record USD 152.2 million, an increase of approximately 12% year-over-year. Adjusted EBITDA was USD 40.9 million, up 20% year-over-year, representing a 27% Margin of revenues, and Net Income totaled USD 21.4 million, up 29% year-over-year.
Raised 2026 Guidance
Management said it is increasing its 2026 annual guidance to a range of USD 205 million to USD 208 million in revenues and USD 52 million to USD 54 million of adjusted EBITDA, with the midpoints representing 14% and 26% growth, respectively, compared with 2025 results. It also said it projects continued double-digit profitable growth in 2027.
Detailed 2027 financial guidance is scheduled to be provided in January, and management said it can already share a projection of another year of double-digit growth in revenues and profitability in 2027.
The company announced another Cash Dividend of USD 0.14 per share, for a total payment of approximately USD 8 million, to be paid to shareholders during the fourth quarter. This is in addition to USD 24.2 million of dividend payments made earlier in the year, bringing the total dividend in 2026 to approximately USD 32.3 million.
Biosimilars, Plasma Supply and Products
In the third quarter, the company announced the commercial launch of two additional biosimilar products in Israel: Ustekinumab-Kamada, a biosimilar to Stelara, and Enoxaparin-Kamada, a biosimilar to Clexane. Management projects its biosimilar portfolio to generate approximately USD 10 million in annual revenues in 2028, growing to approximately USD 20 million to USD 25 million by 2030, and said it plans to launch at least two additional biosimilar products next year.
Management also referred to a three-year sales agreement of approximately USD 50 million announced in July to supply normal source plasma to a leading biopharmaceutical company, with initial sales recorded in the current quarter and already included in guidance. It said the company maintains sufficient KEDRAB supply and Manufacturing capacity for increased Demand in the United States, and continues to support a post-marketing research program for CYTOGAM.
Kamada Q3 2026 Earnings: Key Takeaways
Kamada reported third quarter 2026 revenue of USD 52.03 million and EPS of USD 0.16. Management raised 2026 guidance to USD 205 million to USD 208 million in revenues and USD 52 million to USD 54 million in adjusted EBITDA.






Please wait processing your request...